𝔖 Bobbio Scriptorium

✦ LIBER ✦

Abiraterone acetate, an efficacy treatment option for metastatic castration-resistant prostate carcinoma (mCRPC) that improves functional status in elderly patients (EP)

✍ Scribed by Fratino⁎, L.; Re, G. Lo; Polesel, J.; Channoufi, L.; Muggia, M.; Depangher, V.; Bearz, A.; Spina, M.; Tirelli, U.

Book ID: 122865847
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 68 KB
Volume: 3
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2012.10.103

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7001 ORAL Abiraterone Acetate Improves F

7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study

✍ Harland, S.; de Bono, J.S.; Haqq, C.M.; Staffurth, J.N.; Hao, Y.; Gagnon, D.; Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

127 Improved survival in elderly (≥75 yr

127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study

✍ P.F.A. Mulders; A. Molina; M. Marberger; F. Saad; J.H. Li; T. Kheoh; C.M. Haqq; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 37 KB